| Supplier |
CD BioSciences |
| Product # |
AMA-0445 |
| Pricing |
20 µL/100 µL/300 µL, Inquire
|
| Product Category |
Antibodies
|
| Application |
WB, IHC
|
| Product Usage Information Dilution |
Western Blotting (1:2000); Immunohistochemistry (1:50)
|
| Reactivity |
Human, Monkey
|
| Host |
Mouse
|
| Gene ID |
1026
|
| UniProt ID |
|
| Source/Isotype |
Mouse IgG2a
|
| MW (Target) |
21 kDa
|
| Storage |
Store at -20°C. Do not aliquot the antibody.
|
| Purification |
Monoclonal antibody is produced by immunizing animals with recombinant human p21 corresponding to the amino-terminal portion of p21.
|
| Background |
The tumor suppressor protein p21 Waf1/Cip1 acts as an inhibitor of cell cycle progression. It functions in stoichiometric relationships forming heterotrimeric complexes with cyclins and cyclin-dependent kinases. In association with CDK2 complexes, it serves to inhibit kinase activity and block progression through G1/S However, p21 may also enhance assembly and activity in complexes of CDK4 or CDK6 and cyclin D The carboxy-terminal region of p21 is sufficient to bind and inhibit PCNA, a subunit of DNA polymerase, and may coordinate DNA replication with cell cycle progression Upon UV damage or during cell cycle stages when cdc2/cyclin B or CDK2/cyclin A are active, p53 is phosphorylated and upregulates p21 transcription via a p53-responsive element Protein levels of p21 are downregulated through ubiquitination and proteasomal degradation.
|